Clinicopathologic characteristics of 76 patients with APL receiving different As2O3-containing maintenance regimens
| Parameters . | Value . |
|---|---|
| As2O3 maintenance (regimen A, N = 20) | |
| Male/female | 12:8 |
| Median age, y (range) | 43 (26-73) |
| Median hemoglobin, g/dL (range) | 8.1 (5.4-12.3) |
| Median WBC count, × 109/L (range) | 1.8 (0.3-30) |
| Median platelet count, × 109/L (range) | 16 (6-162) |
| WBC count, > 10 × 109/L | 2 |
| Platelet count, < 40 × 109/L | 14 |
| Previous induction with chemotherapy + ATRA | 20 |
| Leukocytosis > 10 × 109/L during treatment | 8 |
| Median peak WBC count during induction, × 109/L (range) | 6.5 (1.2-90) |
| APL differentiation syndrome | 5 |
| As2O3 + ATRA maintenance (regimen AA, N = 19) | |
| Male/female | 8:11 |
| Median age, y (range) | 54 (16-73) |
| Median hemoglobin, g/dL (range) | 8 (4.8-13.4) |
| Median WBC count, × 109/L (range) | 4.7 (0.5-62) |
| Platelet count, × 109/L, median (range) | 23 (3-78) |
| WBC count, > 10 × 109/L | 5 |
| Platelet count, < 40 × 109/L | 14 |
| Previous induction with chemotherapy + ATRA | 19 |
| Leukocytosis > 10 × 109/L during treatment | 11 |
| Median peak WBC count during induction, × 109/L (range) | 21 (0.8-70) |
| APL differentiation syndrome | 6 |
| As2O3 + ATRA + ascorbic acid maintenance (regimen AAA, N = 37) | |
| Male/female | 15:22 |
| Median age, y (range) | 48 (23-83) |
| Median hemoglobin, g/dL (range) | 7.8 (3.3-14.6) |
| Median WBC count, × 109/L (range) | 19 (0.3-121) |
| Median platelet count, × 109/L (range) | 26 (8-112) |
| WBC count, > 10 × 109/L | 3 |
| Platelet count, < 40 × 109/L | 23 |
| Previous induction with chemotherapy + ATRA | 33 |
| Previous induction with As2O3 + ATRA | 4 |
| Leukocytosis > 10 × 109/L during treatment | 16 |
| Median peak WBC count during induction, × 109/L (range) | 9.2 (0.6-123) |
| APL differentiation syndrome | 5 |
| Parameters . | Value . |
|---|---|
| As2O3 maintenance (regimen A, N = 20) | |
| Male/female | 12:8 |
| Median age, y (range) | 43 (26-73) |
| Median hemoglobin, g/dL (range) | 8.1 (5.4-12.3) |
| Median WBC count, × 109/L (range) | 1.8 (0.3-30) |
| Median platelet count, × 109/L (range) | 16 (6-162) |
| WBC count, > 10 × 109/L | 2 |
| Platelet count, < 40 × 109/L | 14 |
| Previous induction with chemotherapy + ATRA | 20 |
| Leukocytosis > 10 × 109/L during treatment | 8 |
| Median peak WBC count during induction, × 109/L (range) | 6.5 (1.2-90) |
| APL differentiation syndrome | 5 |
| As2O3 + ATRA maintenance (regimen AA, N = 19) | |
| Male/female | 8:11 |
| Median age, y (range) | 54 (16-73) |
| Median hemoglobin, g/dL (range) | 8 (4.8-13.4) |
| Median WBC count, × 109/L (range) | 4.7 (0.5-62) |
| Platelet count, × 109/L, median (range) | 23 (3-78) |
| WBC count, > 10 × 109/L | 5 |
| Platelet count, < 40 × 109/L | 14 |
| Previous induction with chemotherapy + ATRA | 19 |
| Leukocytosis > 10 × 109/L during treatment | 11 |
| Median peak WBC count during induction, × 109/L (range) | 21 (0.8-70) |
| APL differentiation syndrome | 6 |
| As2O3 + ATRA + ascorbic acid maintenance (regimen AAA, N = 37) | |
| Male/female | 15:22 |
| Median age, y (range) | 48 (23-83) |
| Median hemoglobin, g/dL (range) | 7.8 (3.3-14.6) |
| Median WBC count, × 109/L (range) | 19 (0.3-121) |
| Median platelet count, × 109/L (range) | 26 (8-112) |
| WBC count, > 10 × 109/L | 3 |
| Platelet count, < 40 × 109/L | 23 |
| Previous induction with chemotherapy + ATRA | 33 |
| Previous induction with As2O3 + ATRA | 4 |
| Leukocytosis > 10 × 109/L during treatment | 16 |
| Median peak WBC count during induction, × 109/L (range) | 9.2 (0.6-123) |
| APL differentiation syndrome | 5 |